Clinical Trials Logo
  1. Home
  2. Malignant Lymphoma
  3. NCT04698616

Lean Body Mass and Side Effects in Patients With Lymphoma

Malignant Lymphoma Clinical Trial

Official title:
The Relation Between Lean Body Mass and Side Effects Induced by Chemotherapy in Patients With Lymphoma: A Prospective Cohort Study

Clinical Trial Summary

The primary purpose is to investigate the relationship between the dose of chemotherapeutic agents per kilogram of lean body mass (LBM) and the development of side effects induced by chemotherapy in patients with lymphoma. Secondarily, the maximum tolerable dose of chemotherapeutics (MTD), patients' quality of life (QOL), nutritional status and physical activity during the course of treatment are estimated.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04698616
Study type Observational
Source University of Copenhagen
Contact Christian Bjørn Poulsen, MD, PhD
Phone +45 47324809
Email cbpo@regionsjaelland.dk
Status Recruiting
Phase
Start date February 9, 2020
Completion date March 3, 2021
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03346096 - TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma Phase 2
Completed NCT05190263 - Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma
Completed NCT01473095 - Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma Phase 1
Completed NCT00683046 - T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies Phase 2
Recruiting NCT02131688 - Phase I Study of Mitoxantrone Hydrochloride Liposome Injection Phase 1
Completed NCT00892502 - Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? N/A
Completed NCT00685997 - Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas N/A
Not yet recruiting NCT06358001 - EchoTip AcuCore Post-Market Clinical Study
Recruiting NCT04986293 - CPAP or BiPAP for Motion Mitigation During Radiotherapy N/A
Completed NCT01588548 - Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma Phase 1
Withdrawn NCT04464889 - HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation Phase 1
Completed NCT03316144 - Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma Phase 1
Terminated NCT01016795 - Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma Phase 2
Completed NCT04464590 - Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
Active, not recruiting NCT02678299 - Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study Phase 1/Phase 2
Completed NCT01499147 - Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies N/A
Completed NCT01789060 - p-AKT Expression on Clinical Outcomes in Malignant Lymphoma N/A
Completed NCT05827341 - A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials
Active, not recruiting NCT05515029 - Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis Phase 3
Not yet recruiting NCT05545202 - A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation Phase 4